Multiple myeloma diagnosis integrates blood tests, genetic assessments, and imaging to guide personalized treatment and patient engagement. Smoldering multiple myeloma involves active surveillance to ...

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...

The EXCALIBER-RRMM study evaluated the efficacy and safety of iberdomide, an investigational cereblon E3 ligase modulator, in combination with dexamethasone and daratumumab in adults with RRMM.

Bristol Myers Squibb’s (BMS’s) investigational cereblon E3 ligase modulator iberdomide has shown promise in a mid-stage endpoint of a multiple myeloma trial. The ongoing Phase III EXCALIBER-RRMM study ...

Researchers suggest that tailoring interventions to symptom clusters and chemotherapy course may be best management strategy.

Shaji Kumar, MD, Mayo Clinic, explores the potential for earlier intervention and curative approaches in multiple myeloma, and explains how harnessing a patient's immune system through therapies like ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing ...